Endoscopy devices market seen reaching $84.55 billion by 2035

Market Research Future projects the global endoscopy devices market will grow from $45.52 billion in 2026 to $84.55 billion by 2035, driven by easier colonoscopy access, AI-guided detection upgrades and a faster shift to single-use scopes. The forecast points to steady demand across hospitals, outpatient centers and screening programs as reimbursement, infection control and technology refresh cycles reshape purchasing.

Why it matters: - Endoscopy is moving from a specialty procedure business to a larger preventive-screening and AI-upgrade market. - The forecast implies more spending on scopes, visualization towers, software and disposable devices across hospitals and ambulatory surgery centers. - Screening access matters because colorectal detection can change outcomes earlier in the care pathway.

What happened: - Market Research Future projects the global endoscopy devices market will reach $84.55 billion by 2035, up from $45.52 billion in 2026. - The forecast uses a 7.10% compound annual growth rate for 2026 to 2035. - The market base was estimated at $42.50 billion in 2025. - The report links growth to CMS elimination of cost-sharing for screening colonoscopies, AI-guided detection adoption and tighter infection-control rules. - The source also flags increased demand in North America, Europe, Asia-Pacific and the Middle East and Africa.

The details: - CMS removed out-of-pocket costs in January 2024 for Medicare beneficiaries undergoing screening colonoscopies, including cases where a polyp is found and removed. - Early utilization data from the American Gastroenterological Association showed a 14% rise in scheduled colonoscopies in the first nine months after implementation. - The report says more than 18 FDA 510(k) clearances for computer-aided detection and diagnosis modules were issued between 2022 and 2025. - Clinical trials cited in the report showed a 30% to 40% improvement in adenoma detection rates versus unaided white-light endoscopy. - The report says hospitals are replacing older visualization systems installed between 2012 and 2018 with 4K-capable platforms and cloud-based image archiving. - The report estimates AI-linked hardware replacement could drive $2.1 billion in incremental equipment sales by 2028. - Between 2024 and 2026, the FDA issued 12 safety communications about contamination risks tied to reprocessed duodenoscopes. - Disposable scopes still cost 35% to 50% more per procedure, but the report says total cost of ownership narrows to about 12% after reprocessing and liability costs. - Single-use devices eliminate 30 to 60 minutes of reprocessing time per procedure. - China added upper-GI screening coverage in its 2025 National Cancer Screening Program, extending access to more than 1.3 billion insured lives. - India’s Ayushman Bharat scheme and China’s screening program together are described as making gastrointestinal screening accessible to more than 900 million previously underserved people. - Endoscopes held about 46.2% of device revenue in 2025. - Visualization equipment was the fastest-growing device segment, with an 8.90% CAGR projected for 2026 to 2035. - Gastrointestinal applications accounted for about 59.4% of revenue in 2025. - Laparoscopy was the fastest-growing application segment, with a 9.50% CAGR projected for 2026 to 2035. - Reprocessed and reusable devices represented about 85.5% of usability revenue in 2025. - Single-use devices were the fastest-growing usability segment, with an 11.75% CAGR projected for 2026 to 2035. - Hospitals held about 52.3% of end-user share in 2025. - Ambulatory surgical centers were the fastest-growing end-user segment, with a 10.45% CAGR projected for 2026 to 2035.

Between the lines: - The market outlook is being shaped less by discretionary demand and more by reimbursement, screening policy and infection-control compliance. - AI compatibility is shortening replacement cycles for older equipment and pushing hospitals to refresh full visualization stacks rather than individual components. - The rise of single-use scopes suggests providers are weighing workflow speed and contamination risk against higher per-case prices. - Regional growth is not uniform. The US and China appear to be the biggest demand engines because of reimbursement and screening expansion. - The competitive field remains concentrated, with the top five companies holding an estimated 58% to 64% of revenue. - Olympus, Medtronic, Boston Scientific, Johnson & Johnson and Karl Storz are positioned around GI scopes, AI modules, therapeutic tools and visualization platforms.

What's next: - The report expects AI-integrated endoscopy to become a standard operating model by 2030. - By 2030, about 40% of newly diagnosed colorectal lesions are expected to receive AI-enhanced detection followed by matched therapy, according to the forecast. - Startup investment in endoscopy decision-support tools has topped $800 million since 2023, suggesting more product launches ahead. - The report points to continued demand for 4K systems, cloud archiving, CADe/CADx software and single-use devices as hospitals and outpatient centers upgrade. - More information is available in the company's announcement and the sample request page.